Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the “Company”, an emerging leader in age-reversal science, today announced significant findings from its copper binding studies with Telomir-1. This is ...
VYN202 induced a dose-dependent increase in the target engagement biomarker HEXIM-1 1 with a maximal effect observed at 0.5mg to 1.0 mg QD. For more information on the Phase 1a trial results, please ...